Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment
August 30 2023 - 7:49AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced that physicians at Overland Park Regional Medical Center
(OPRMC) launched and successfully completed the first procedures
using the advanced Genesis Robotic Magnetic Navigation (RMN)
System.
OPRMC – part of HCA Midwest Health, Kansas
City’s largest healthcare provider – is the only hospital in the
U.S. to offer two Stereotaxis Robotic Magnetic Navigation systems
for patients receiving minimally invasive cardiac ablation
procedures. It is among the first in the nation to adopt the latest
Genesis RMN system. First established in 2019, the robotic heart
rhythm care program at OPRMC has become a leading practice using
advanced robotic technology to treat a broad range of arrhythmias,
including those often considered too challenging or dangerous for
traditional approaches.
“Establishing a second robotic electrophysiology
lab allows for additional capacity and opportunities to provide the
high-quality, compassionate patient care we are known for to the
communities we serve,” says Overland Park Regional Medical Center
CEO Matt Sogard. “The adoption of the innovative robotic magnetic
navigation technology represents our continued commitment to the
area’s growing healthcare demands, offering healing and hope for
heart patients and families.”
One of the first patients treated with the new
Genesis robot was Bill Kellogg, RN, BSN, RCIS. Mr. Kellogg works as
an electrophysiology clinician at OPRMC caring for arrhythmia
patients and is himself a patient. After years of living with
atrial fibrillation, Mr. Kellogg experienced a critical arrhythmia
called ventricular tachycardia. He was treated with the Genesis RMN
system shortly after its installation.
“I’ve worked with Dr. Lakkireddy in the EP lab
at Overland Park Regional Medical Center since 2018 and had
complete confidence in him,” said Mr. Kellogg. “The procedure used
the new robotic magnetic navigation system. The ablation was on a
Monday and by Thursday I was doing dishes and laundry. I feel great
today. I’m so blessed to have had my procedure done where I did,
when I did, with the best physician, equipment, and staff. I
appreciate it all so much. I feel this happened for a reason, and
one of those reasons is how I approach the patients who we care
for. I can keep them at ease by sharing my experience, and let them
know they are in great hands, as the team, headed by Dr.
Lakkireddy, saved my life.”
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias –
abnormal heart rhythms that result when the heart beats too
quickly, too slowly, or with an irregular pattern. When left
untreated, arrhythmias may significantly increase the risk of
stroke, heart failure, and sudden cardiac arrest.
“The initial procedures with Genesis went very
well,” said Dhanunjaya “DJ” Lakkireddy, MD, Electrophysiologist and
Executive Medical Director of Kansas City Heart Rhythm Institute at
Overland Park Regional Medical Center. “We are pleased to be the
first in the nation to offer two advanced robotic cardiac ablation
systems to countless individuals suffering from arrhythmias,
helping improve patient outcomes.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global
leader in innovative surgical robotics for minimally invasive
endovascular intervention. Its mission is the discovery,
development and delivery of robotic systems, instruments, and
information solutions for the interventional laboratory. These
innovations help physicians provide unsurpassed patient care with
robotic precision and safety, expand access to minimally invasive
therapy, and enhance the productivity, connectivity, and
intelligence in the operating room. Stereotaxis technology has been
used to treat over 100,000 patients across the United States,
Europe, Asia, and elsewhere. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2024 to May 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From May 2023 to May 2024